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The effect of free muramyl tripeptide phosphatidylethanolamide (MTPPE) and liposome-encapsulated
MTPPE (LE-MTPPE) on KlebsieUa pneuwnoniae septicemia resulting from intraperitoneal bacterial inoculation
was investigated in mice. When administering a single prophylactic dose at 24 h before bacterial inoculation,
the percentage survival was 55% (MTPPE) or 40% (LE-MTPPE), whereas untreated control mice died. Only
repeated prophylactic treatment with LE-MTPPE could further increase survival up to 85%.
In the immunocompromised host, severe infections are
difficult to treat with antibiotics. One of the factors that
contribute to this lack of success of antibiotic treatment is
the failure of the host defense to give adequate support. In
this respect it is of great importance to stimulate the non-
specific host defense, in particular, the mononuclear phago-
cyte system (MPS). This can be effected by the immunomod-
ulating agent muramyl tripeptide phosphatidylethanolamide
(MTPPE).
MTPPE is a lipophilic derivative of muramyl dipeptide.
Muramyl peptides have various stimulating effects on mac-
rophages (6, 7, 14, 22, 24) and have been proven to be
effective in stimulating the nonspecific host defense against
several bacterial infections (20, 21). In a previous study (16),
we investigated the effect of MTPPE in a model of infection
induced by intravenous (i.v.) inoculation ofKlebsiella pneu-
moniae in mice. K pneumoniae is one of the pathogens
cultured from samples from infected hospitalized patients
and is a serious complication in patients with malignancies
(3). Since these immunocompromised patients are mostly
prone to infections during a prolonged period of time, it is
expected that repeated administration of immunomodulating
agents is needed. Repeated administration of MTPPE has
been shown to result in toxic side effects (2, 5, 25). Encap-
sulation of MTPPE in liposomes may therefore be of impor-
tance, since in this form a reduction in MTPPE toxicity has
been demonstrated (5, 25). In addition, because of liposomal
encapsulation, MTPPE is targeted to the cells of the MPS
(13, 16). In the present study, we used an infection model in
which K pneumoniae was inoculated intraperitoneally
(i.p.), resulting in the appearance ofK pneumoniae in the
blood at regular intervals, eventually leading to septicemia.
This model has a clinical relevance because immunocompro-
mised patients are also prone to the development of septi-
cemia from a local infection. The efficacy of several prophy-
lactic and therapeutic treatment schedules with free MTPPE
or liposome-encapsulated MTPPE (LE-MTPPE) was inves-
tigated in immunocompetent as well as leukopenic mice.
Infections were induced by i.p. inoculation of 103 CFU of
K pneumoniae ATCC 43816 capsular serotype 2 into spe-
cific-pathogen-free, 11- to 13-week-old male C57BL/Ka mice
* Corresponding author.
(ITRI-TNO, Rijswijk, The Netherlands). The 50% lethal
dose after i.p. inoculation was less then 10 CFU (500
CFU/kg of body weight). Mice were injected with MTPPE,
LE-MTPPE, placebo liposomes (a generous gift of CIBA
GEIGY Ltd. Basel, Switzerland), or phosphate-buffered
saline (PBS) by following various treatment schedules. Each
comparison group contained 20 mice. Liposomes were pre-
pared as described by Van Hoogevest and Frankenhauser
(26). Then, mice were housed in separate cages, and every
day the survival of mice was examined until 21 days after
bacterial inoculation. From dead mice onlyK pneumoniae
was recovered from the blood.
In some of the mice, leukopenia was induced by i.p.
injections of cyclophosphamide (Sigma Diagnostics, St.
Louis, Mo.) at a first dose of 120 mg/kg at 11 days before
bacterial inoculation and then at doses of 80 mg/kg every
third day thereafter. To quantify the numbers of leukocytes
in blood, blood samples (0.8 ml) were taken from the
retroorbital plexus and were collected in polypropylene
tubes containing 1 mg of dried EDTA (BDH Chemicals Ltd.,
Poole, England). For total leukocyte counts, blood was
diluted 1:10 with Turk solution (0.1% crystal violet in 1%
acetic acid), and the number of leukocytes was determined
in duplicate in a Burkers hemocytometer. The clearance
capacity of these leukopenic mice was compared with that of
immunocompetent mice as follows. At different intervals
after i.v. inoculation with 104 CFU ofK pneumoniae, blood
samples (0.8 ml) were taken as described above. Serial
10-fold dilutions were prepared and volumes of 0.2 ml of
each dilution were spread onto tryptone soy agar plates
(Oxoid Ltd., Basingstoke, England). All plates were incu-
bated overnight at 26°C.
Statistical evaluation of the differences in the decrease in
survival with time as well as the eventual percentage of
survival between the MTPPE-treated, LE-MTPPE-treated,
PBS-treated, and placebo liposome-treated groups of ani-
mals was performed by the log rank test (17). The Mann-
Whitney test was used for evaluation of the differences in the
numbers of leukocytes and bacteria between the LE-
MTPPE-treated and PBS-treated groups of animals.
After i.p. inoculation of mice with 103 CFU of K pneu-
moniae, bacteria appeared in the blood and reached levels of
103 to 104 CFU ofK pneumoniae per ml of blood within 4 h
and 106 CFU per ml blood after 2 days. Eventually, all mice
147
ANTIMICROB. AGENTS CHEMOTHER.
6
0
0
lL
n
J-U-
0)
0
-i
5
4
3
2
1
0
0 24 48
Time (h)
FIG. 1. Numbers of K pneumoniae in the blood of mice after
i.p. inoculation. At 24 h before i.p. inoculation with 103 CFU K
pneumoniae, mice were treated i.v. with PBS. Each point repre-
sents the geometric mean standard error of the mean for six mice.
died (by day 3) (Fig. 1). Administration of a single dose of 50
,tg of free MTPPE at 24 h before bacterial inoculation
resulted in maximal survival of 55%. With a dose of 100 ,ug
of free MTPPE, the survival rate was not increased. From a
twofold dose range, 6.3 p,g of MTPPE per mouse was the
lowest dose that resulted in a significantly increased survival
rate compared with that for PBS-treated mice.
Table 1 shows that administration of 25 jig of LE-MTPPE
per mouse at 24 h before bacterial inoculation resulted in the
survival of 40% of the mice. A dose of 6.3 mg of placebo
liposomes, which is equivalent to the amount of lipid in
which 25 ,g of MTPPE is encapsulated, had no effect. A
dose of 25 ,ug of LE-MTPPE was the maximum dose that
could be administered, since at higher doses the equivalent
amount of placebo liposomes had toxic effects. From a
twofold dose range, 3.1 ,ug of LE-MTPPE per mouse was the
lowest dose that resulted in a significantly increased survival
rate compared with that for PBS-treated mice. Administra-
tion of additional therapeutic doses of 3.1 ,ug of LE-MTPPE
could improve the effect of administration of a single dose of
3.1 ,ug at 24 h before bacterial inoculation. Depending on the
interval, survival was increased to 35% (three doses every 48
h) or 55% (three doses every 24 h). Repeated administration
of 0.8 mg of placebo liposomes, equivalent to the amount of
lipid in which 3.1 ,tg of MTPPE was encapsulated, had no
effect.
Repeated prophylactic administration of doses of 3.1 ,ug of
LE-MTPPE resulted in the best percent survival (Table 1).
Depending on the number of doses and the interval, survival
was increased to 85% (four doses every 48 h) or 75% (four
doses every 24 h). Repeated administration of 0.8 mg of
placebo liposomes with an interval of 48 h had no effect.
Repeated administration of 0.8 mg of placebo liposomes at
an interval of 24 h also resulted in a significantly increased
survival (5%) compared with that for PBS-treated mice (P =
0.04).
Table 1 also shows that in cyclophosphamide-treated
leukopenic mice infected i.p. with 103 CFU of K pneumo-
niae, prophylactic administration of four doses of 3.1 ,ug of
LE-MTPPE at an interval of 48 h (the treatment schedule
which was most effective in immunocompetent mice) led to
TABLE 1. Efficacies of LE-MTPPE treatment schedules on K pneumoniae septicemia in mice
Mice and time (h) of Dose (,ug) % Survival Time to death Significancec
administrationa (days)b
Immunocompetent mice
-24 h 25 40 6.9 4.8 0.001
-24 12.5 20 5.8 ± 2.7 0.001
-24 6.3 10 4.3 + 1.7 0.05
-24 3.1 5 4.4 ± 1.2 0.01
-24 0 0 3.6 0.9
-24, +24 25 30 6.7 ± 2.8 0.001
-24, +24, +72 25 45 7.2 ± 4.0 0.001
-24, +24 3.1 30 4.6 ± 1.4 0.001
-24, +24, +72 3.1 35 5.2 ± 2.3 0.001
-24, 0 3.1 45 4.5 ± 1.5 0.001
-24, 0, +24 3.1 55 4.5 ± 1.7 0.001
-72, -24 3.1 40 3.7 ± 0.9 0.001
-120, -72, -24 3.1 70 6.8 ± 3.9 0.001
-168, -120, -72, -24 3.1 85 7.0 ± 1.6 0.001
-48, -24 3.1 40 6.8 ± 2.2 0.001
-72, -48, -24 3.1 75 3.4 ± 0.5 0.001
-96, -72, -48, -24 3.1 75 4.8 ± 0.8 0.001
Leukopenic mice
-168, -120, -72, -24 3.1 5 4.2 ± 0.9 0.001
0 0 2.2 ± 0.4
a LE-MTPPE was administered at the indicated times before (-) or after (+) bacterial inoculation (day 0).
b Values are means ± standard deviations on the basis of the time of bacterial inoculation (day 0).
c Versus PBS-treated mice.
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TABLE 2. Clearance ofK pneumoniae from the blood of normal
and leukopenic micea
Log no. of K pneumoniaelml blood at the following times
Mice after i.v. bacterial inoculationb
1 min 15 min 30 min 60 min
Normal 3.80 + 0.05 3.15 ± 0.05 3.01 + 0.14 3.05 + 0.10
Leukopenic 3.80 ± 0.05 3.29 ± 0.08 3.25 + 0.14 3.06 ± 0.13
a Normal and leukopenic mice were inoculated i.v. with 104 CFU of K
pneumoniae.
b Values are geometric means ± standard errors of the mean for six mice.
an increased survival rate compared with that in PBS-treated
leukopenic mice. The numbers of total leukocytes in the
blood of LE-MTPPE-treated leukopenic mice did not differ
from the numbers in PBS-treated leukopenic mice. They
were 670 + 25 and 687 + 26/,u of blood (mean ± standard
error of the mean for six mice), respectively. In PBS-treated
immunocompetent mice, leukocyte numbers fluctuated
around 3,700/,l of blood. The cyclophosphamide treatment
in itself did not lead to a decreased capacity of the MPS to
clearK pneumoniae from the blood in comparison with the
clearance capacity of the MPS of PBS-treated immunocom-
petent mice (Table 2).
Administration of a single dose of MTPPE, LE-MTPPE,
muramyl dipeptide (MDP), or other MDP derivatives
seemed to be most effective when the dose was given at 24 h
before bacterial inoculation (1, 16, 20). Administration of a
single dose of LE-MTPPE after bacterial inoculation did not
appear to be effective (16). The results obtained with re-
peated administration of MDP derivatives were discrepant
(4, 8, 11, 12, 19, 21). Various microorganisms were used
(viruses, bacteria, or parasites), and in most studies only a
few treatment schedules were compared. However, a de-
tailed study related to the effects of prophylactic or thera-
peutic treatment schedules for MDP derivatives has not yet
been performed.
Investigations on the efficacy of repeated administration of
immunomodulating agents are of clinical relevance since
immunocompromised patients are prone to infections during
a prolonged period of time. Results of the present study
show that the greatest therapeutic effect was obtained when
all doses of LE-MTPPE were given prophylactically at an
interval of 48 h. This indicates that time is needed for
macrophages to become maximally activated. This may be
the result of the direct stimulation by LE-MTPPE but also by
products released by activated macrophages, such as inter-
leukin-1 or tumor necrosis factor. In addition, more macro-
phages may be activated during this period of prophylactic
administration. In future studies, the activation state and the
involvement of cytokines and other cell types in the LE-
MTPPE-induced resistance against K pneumoniae infection
will be elucidated.
In the present study, we also investigated the effect of
stimulating host defenses in leukopenic mice. These mice
were immunocompromised as a result of treatment with
cyclophosphamide, resulting in a 82% decrease in the num-
bers of peripheral leukocytes. The effects of repeated pro-
phylactic administration of LE-MTPPE in terms of the
increased survival rate and increased percent survival ob-
served in immunocompetent mice could also be found in
leukopenic mice. Other investigators (9, 10, 21, 23) assessed
only the effect of single doses of the MDP derivative
administered at 24 h before bacterial inoculation.
Whereas in immunocompetent mice we previously found
increased numbers of leukocytes in the blood as a result of
LE-MTPPE treatment (16), the present study demonstrated
that, in cyclophosphamide-treated leukopenic mice, the
numbers of leukocytes in the blood were not increased after
repeated administration of LE-MTPPE. This was due to the
cyclophosphamide-induced blockade of the recruitment of
leukocytes. It can be concluded that the LE-MTPPE-in-
duced recruitment of leukocytes does not contribute sub-
stantially to the therapeutic effect of LE-MTPPE. Activation
of tissue macrophages by LE-MTPPE is of major importance
in the induced antibacterial resistance in leukopenic mice. In
immunocompetent mice, we also found that activation of
tissue macrophages is of great importance in the increased
resistance againstK pneumoniae infections (15). Our results
are in agreement with the findings of Nakajima et al. (18),
who indicated that leukocyte numbers in the blood of
cyclophosphamide-treated mice were not increased after
treatment with the lipophilic MDP-Lys (L18).
This study was supported by the Jan Dekkerstichting & dr
Ludgardine Bouwmanstichting.
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